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Abstract
Transmission electron microscopy was used to determine
how immunogold labeling of PKC-a or -3 is modulated
by the antitumor drug IFN (HuIFN a-2b) in the
cytoplasm, membrane strudures, and nucleus of rapidly
dividing and confluent human glioma U-373 cells.
Results showed that except for nuclear localization,
there were no specific cytoplasmic organelles that PKC-
a or -3 translocated to following HuIFN a-2b treatment.
Eledron micrographs of PKC-fi in proliferating cells
depicted 1 .34-fold more PKC- in the nucleus than in
the cytoplasm and a 1-mm HuIFN a-2b (500 units/mI)
treatment transiently increased PKC-fi immunoreadivity
in the cytoplasm (1 .95-fold) and nucleus (1 .97-fold). In
confluent cells, incubation with HuIFN a-2b for 2 mm
significantly decreased cytoplasmic PKC-g3
immunoreactivity by 37%, and no change was observed
in nuclear PKC-fJ labeling. PKC-a labeling in
proliferating cells showed similar immunoreadivity in
both control cytoplasm and nucleus. Treatment of
proliferating cells with HuIFN a-2b for 2 mm decreased
PKC-a in the cytoplasm (59%) and nucleus (44%). In
confluent cells, cytoplasmic PKC-a labeling decreased
59% at 1 mm, 61% at 2 mm, and 76% at 10 mm of
HuIFN a-2b treatment. Nuclear PKC-a decreased by
65% at 1 mm, 80% at 2 mm, and 62% at 10 mm after
HuIFN a-2b treatment. Western blots of total PKC-a in
proliferating and confluent cells and PKC-13 in confluent
cells showed similar results. However, Western blots of
total PKC-a and -3 in proliferating cells did not
demonstrate any significant changes in either PKC-a or
-13 immunoreadivity following 1 -mm HuIFN a-2b
treatment. These results suggest that treatment of
proliferating U-373 cells with HuIFN a-2b for 1 mm
unfolds and exposes PKC-fi antigenic sites (hinge region)
and increases in situ PKC- immunogold labeling.
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lntrodudion
PKC3 is a family of 1 1 isozymes that are phospholipid-
dependent serine/threonine kinases found in varying ratios
in the cytosolic and membrane fractions ofcells, depending
on the type oftissue and its physiological state (1-3). Protein
kinase C isozymes may regulate different cellular functions
and proliferation by phosphorylating intracellular proteins
in response to transmembrane signals from hormones,
growth factors, neuro-transm itters, and pharmacological
agents (4). Activation of PKC by various agonists (including
IFNs) results in altered transcription of a considerable num-
ber of genes (5, 6). Protein kinase C is the major receptor for
tumor-promoting phorbol esters, and PKC isozymes are
abundant in brain tissue (7). However, the extent of PKC
involvement in cellular malignancy is not clearly defined.
Various studies indicate that increased tumonigenicity is
associated with dysregulation of PKC activity, from changes
in PKC concentration, or from both (8-1 2). Inherently high
levels of PKC (1 0, 1 1) have been functionally linked with
the rapid proliferation rates of high-grade gliomas.
Since there are 1 1 PKC isozymes, it is believed that PKC
isozymes within a single cell type may be differentially
regulated by extra- and intracellular stimuli and thereby
i nfluence growth, proliferation, differentiation, metabolism,
and transformation via distinct mechanisms in different sub-
cellular compartments (1 , 2). However, direct ultrastruc-
tural evidence for the association of PKC isozymes with
specific intracellular organelles, thereby suggesting specific
functions for the different PKC isozymes, is limited. To date,
the only PKC isozyme ultrastructural localization study re-
ported is that of Chida et a!. (1 3). They found that PKC-i is
localized on the rough endoplasmic reticulum of COS1
cells that transiently expressed PKC-. In addition, predom-
inant expression of PKC-i was found in differentiated or
differentiating epithelial cells, suggesting a role for PKC-ij in
epidermal differentiation.
Other studies have used cell fractionation techniques to
determine the intracellular location of PKC isozymes, but
these methods may artificially distort the true location of
proteins, and immunofluorescent microscopy cannot dis-
tinguish between PKC translocation to the peninuclear, in-
tranuclear, or microsomal membranes following agonist
treatment (reviewed in Ref. 14).
HuIFN a-2b was studied since it is antiproliferative to-
wards glioma U-373 and activates PKC in these cells (15,
1 6). It is thought that the response of U-373 glioma cells to
HuIFN a-2b is related to the redistribution (movement) of
PKC isozymes within the cell. Here we demonstrate the use
of immunogold labeling and TEM as a method to ultrastuc-
turally study PKC activation and translocation within the
cytoplasm, nucleus, membrane organelles, or cytoskeletal
3 The abbreviations used are: PKC, protein kinase C; TEM, transmission
electron microscopy; HuIFN a-2b, human IFN a-2b; RT-PCR, reverse tran-
scription-PCR; DPBS, Dulbecco’s PBS.
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structures following agonist treatment. The distribution of
PKC-a and -j3 was evaluated in U-373 glioma cells at two
different growth rates and saturation densities following
HuIFN a-2b treatment.
It is well known that astrocytomas are extremely hetero-
geneous tumors and vary within standard tumor grades in
their morphology, differentiation, and types and amounts of
PKC isozymes (17, 18). The U-373 glioma cell line used
here was originated by Jan Ponten from a Grade 3 (highly
proliferative) astrocytoma (1 9). Protein kinase C-a and -13
were analyzed because Western blots of U-373 total cell
(cytosolic, membranous, and nuclear) PKC probed with
polyclonal antibodies to PKC-a and -13 demonstrated im-
munoreactivity for PKC-cs and to a lesser degree for PKC-13
(131 and 1311) when compared to brain extracts. Todo et a!.
(1 8) also found moderately positive type II (PKC-13) immu-
noreactivity with mAbs in all their astrocytomas examined
and weak immunoreactivity for type I (PKC-a) in four of
seven astrocytomas (Grade 2) and two of two anaplastic
astrocytomas (Grade 3). However, controversy exists sur-
rounding the question as to whether PKC 131 or 1311 are
expressed in human astrocytomas. Other workers have not
detected either PKC-f3l or -1311 by immunohistochemistry,
Northern blots, or immunoblotting (20, 21). In this study,
we used the technique of RT-PCR, which is more sensitive
and specific to demonstrate expression of PKC-13l and -1311
mRNA (22). To our knowledge, this is the first in situ im-
muno-ultrastructural study examining PKC-a and -13 move-
ment following agonist treatment.
Results
Demonstration of PKC-3I and -3lI mRNA in U-373 Human
Glioma Cells. Since glioma PKC-f3 expression was debat-
able, we demonstrated the presence of PKC-131 and -1311
mRNA in U-373 glioma cells used here by RT-PCR (22, 23).
Antisense PKC-f31 and -1311 oligonucleotide primers were
synthesized to amplify the nucleotide sequences in the
COOH-terminal variable (V5) regions of PKC-13l and -1311
cDNA. A sense primer corresponding to the hinge or third
variable region (V3) common to PKC-131 and -1311 were used
to amplify cDNA. These primers amplified the catalytic
region of PKC-13 including the alternative splice site for
PKC-131 and -1311. Fig. 1 demonstrates that mRNA transcripts
to PKC-j3l and -1311 are present in U-373 glioma cells.
Western Blots Demonstrate PKC-a, -fil, -all, and -3 in
U-373 Human Glioma Cells. The presence of PKC-a, -131,
-1311, and f3 (131 and j3ll) in U-373 glioma cells was demon-
strated with isozyme-specific antibodies (Fig. 2) by repre-
sentative immunoblots. Direct comparison of the immuno-
reactive polypeptides demonstrated that U-373 total
(cytosolic, membrane, and nuclear) immunoreactivity was
PKC-a > PKC-f3. For the ultrastructural studies and Western
blots mentioned below, we used PKC-cs and -13 antipeptide
antisera.
Monospecificity of PKC-a and -3 Antipeptide Antisera.
Confluent U-373 glioma cells were treated with HuIFN
cs-2b (500 units/mI) for 0, 1, 2, or 10 mm, and total cell
homogenates were used for Western blots. Peptides to
PKC-cs and -/3 were coincubated overnight with antipeptide
antisera and used in Western blot blocking experiments. No
immunoreactive staining was detected in total cell homo-
genates of U-373 cells treated with HuIFN cs-2b for 0, 1 , 2,
or 10 mm and probed with antipeptide antisera to PKC-a
and -13 (Fig. 3). These results demonstrate that antipeptide
SI fill
A B
Fig. 1. Detection of PKC-f3l and PKC-j311 transcripts in U-373 glioma cells
by RT-PCR. Isolation of total U-373 glioma RNA and RT-PCR was carried out
as described in “Materials and Methods.” PCR products were separated on
agarose gels and visualized by ethidium bromide staining. A, PKC-f3l; B,
PKC-)3ll.
antisera are mono-specific for PKC-a and -13 and that cross
reactions with other U-373 glioma cellular proteins can be
eliminated from consideration.
Immunofluorescence and Immunogold Eledron Micros-
copy of U-373 Glioma Cells Treated with HuIFN a-2b.
We initially used indirect immunofluorescent light micros-
copy to determine if changes in the intracellular localiza-
tion of PKC-a or -13could be observed in U-373 glioma cells
following HuIFN a-2b treatment. Rapidly dividing and con-
fluent cultures of U-373 glioma cells were treated with
HuIFN a-2b for 0, 1, 2, and 10 mm and processed for
immunofluorescence using fluorescein-conjugated second
antibodies. Incubation of control U-373 glioma cells with
nonimmune sera showed no detectable autofluorescence
(Fig. 4A). Treatment of control U-373 glioma cells with
antibodies to PKC-13 demonstrated immunofluorescent Ia-
beling in the cytoplasm, nuclear, and peninuclear regions
(Fig. 48). Compared to controls, no dramatic changes in
immunofluorescent PKC-cs or -13 patterns were observed for
the entire series of HuIFN a-2b treated U-373 glioma cells
(data not shown).
Immunogold electron microscopy was used to identify
the intracellular sites to which PKC-a or -13 associate fol-
lowing HuIFN a-2b treatment. As a positive control, glu-
cocorticoid receptor translocation was used to optimize the
technique of immunogold ultrastructural translocation.
Glucocorticoids are used in glioma chemotherapy to inhibit
tumor-induced edema and postoperative brain swelling.
Glucocorticoid receptors are predominantly cytoplasmic in
the absence of steroids. Upon binding of the glucocorti-
coids to the receptor, the hormone-receptor complexes
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translocate to the nucleus, where they affect transcription
and gene expression (Ref. 24; reviewed in Ref. 25). To test
for ultrastructural translocation, U-373 glioma cells were
incubated for various times with 0.025 mi dexamethasone
(a synthetic glucocorticoid) and were processed for immu-
nogold labeling using antibody to the glucocorticoid recep-
tor. Controls for nonspecific labeling using nonimmune
rabbit serum and control sections of U-373 glioma demon-
strated minimal staining (Fig. 5A). As shown in Fig. 58,
control U-373 cells assayed with anti-glucocorticoid recep-
tor showed sparse labeling restricted to the cytosol. To
enhance the visibility of the gold particles, sections in Fig.
5, B and C, were not contrast stained with lead citrate.
Examination of U-373 cells treated with dexamethasone for
2 mm and labeled with the anti-glucocorticoid receptor
showed the majority of the gold particles associated with
the nucleolus (the site of nuclear transcription). These re-
suits suggest that agonist-induced ultrastructural transloca-
tion can he documented with immunogold labeling.
Fig. 3. Western 1)101 analysis of
antipeptide antisera blocked with
peptides to PKC-cs and -(3. Glioma
U. 373 cells were treated with
DPBS (controls) or HuIFN a-2b
500 units/mI) for 1, 2, or 10 mm.
Total cell homogenates were pre-
pared by sonicating cells in ho-
mogenization buffer containing
1”/,, Triton X-100 (see “Materials
and Methods”). Peptides to PKC-o
and -(3 (300 pI containing too pg
were incubated overnight with 1
ml of milk and 50 pl of antibody.
The coincubated antibody and
peptide mixture was turther di-
luted 7:1000 for Western blots
and chemiluminescence. Protein
concentration loaded/well was
100 pg for PKC-cr detection and
200 pg br assaying PKC-(3.
Subsequently, the ultrastructural effects of HuIFN a-2b
on PKC-cs and -13 stimulation were evaluated in cross-sec-
tional profiles of U-373 glioma cells treated with HuIFN
a-2b for 0, 1, 2, and 10 mm under the TEM. In rapidly
dividing (75% confluent) U-373 glioma cells, the distribu-
tion of PKC-f3 immunogold particles in untreated cytoplasm
and nucleus was significantly different (Fig. 6A). There was
1 .34- and 1 .27-fold more PKC-13 labeling in the nucleus
compared to the cytoplasm in proliferative and confluent
cells, respectively (Fig. 6). However, treatment of rapidly
dividing cells with HuIFN a-2b for 1 mm abruptly and
significantly increased PKC-13 labeling in both the cyto-
plasm (1 .95-fold) and nucleus (1 .97-fold) compared to un-
treated cells (Fig. 6A). Following 2 mm incubation of pro-
liferating cells with HuIFN a-2b, cytoplasmic and nuclear
PKC-13 immunoreactivity transiently declined to near basal
levels, and at 1 0 mm after HuIFN a-2b treatment, cytoplas-
mic (44%) and nuclear (50%) PKC-j3 decreased to below
basal levels (Fig. 6A). In contrast, no significant modulation
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Fig. 4. Fluoresein indirect inimunofluorescence micrographs of U-373
glioma cells. Control U-373 cells incubated with nonimmune rabbit serum
A) and rabbit anti-PKC-13 (B). See “Materials and Methods” for experimental
details. X 450.
of nuclear PKC-/3 was observed in confluent cells at any of
the incubation time points examined (Fig. 68). Cytoplasmic
PKC-13 immunoreactivity in confluent cells did not change
at 1 mm after HuIFN a-2b. However, at 2 mm after HuIFN
a-2b treatment, there was a significant decrease (34%) in
PKC-p labeling compared to controls. Cytoplasmic PKC-f3
immunoreactivity approached basal levels at 10 mm after
HuIFN a-2b treatment.
The temporal effects of HuIFN a-2b on PKC-13 ultra-
structural localization in rapidly dividing cells showed
PKC-f3 labeling distributed between the cytoplasm and
nucleus under basal conditions (Fig. 7). increased cyto-
plasmic and nuclear PKC-13 labeling was observed at 1
mm following HuIFN a-2b treatment (Fig. 7, Cand D). In
confluent cells, nuclear PKC-p labeling was approxi-
mately equal at all time points after HuIFN a-2b treat-
ment (Fig. 8). in contrast, cytoplasmic PKC-p in confluent
cells decreased at 2 mm following Hu1FN a-2b treatment.
Examination of subcellular organelle labeling in prolifer-
ating and confluent cells (Figs. 7 and 8) depicted prom-
inent PKC-13 staining in the nucleus (euchromatin, het-
erochromatin, and nucleolus). Immunogold particles
specific to PKC-13 were associated with plasma mem-
brane, mitochondria, lysosomes, lipid droplets, rough
and smooth endoplasmic reticulum, and Goigi
complexes.
Quantitative evaluation of PKC-a immunogold labeling
in proliferating cells showed sparse immunoreactivity
equally distributed in both untreated cytoplasm and nu-
cleus (Fig. 9A). Incubation with Hu1FN a-2b for 1 mm
yielded no significant change in either PKC-a cytoplasmic
or nuclear distribution. Following 2 mm of HuIFN ct-2b
treatment, cytoplasmic (59%) and nuclear (44%) PKC-a
immunoreactivity decreased. By 10 mm after HuIFN ct-2b
Fig. 5. Immunogold transmission electron micrographs of U-373 human
glioma cells. Control U-373 cells incubated with nonimmune rabbit serum
(A) at 1 :20 dilution and rabbit anti-glucocorticoid receptor (B) at 1 :400
dilution. C, glioma U-373 treated with dexamethasone (0.025 m.i) for 2 mm
and assayed with rabbit anti-glucocorticoid receptor at 1 :400 dilution. Col-
loidal gold protein A was diluted 1 :50. A, X 25287; B, X 25287; C, X 30742.
C, cytoplasm; n, nucleus; Nu, nucleolus; gt glial filaments; L, lipid droplets.
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61% at 2 mm, and 76% at 10 mm of HuIFN a-2b treat-
ment. Nuclear PKC-a decreased by 65% at 1 mm, 80% at
2 mm, and 62% at 10 mm after HuIFN a-2b treatment.
Ultrastructural analysis of PKC-a organelle labeling pat-
tern in proliferating cells (Fig. 10) illustrated enhanced
staining in the nucleus and equal labeling between all
other organelles at all HuIFN a-2b time points studied.
Alternatively, analysis of PKC-a labeling in confluent
cells (Fig. 1 1) showed random labeling in both the cyto-
plasm and nucleus and no specific PKC-cr organelle
association was found.
Western Blots of Total PKC-a and PKC-fl in Proliferating
and Confluent U-373 Cells following HuIFN a-2b Treat-
ments. To determine if modulation of PKC-a and -/3 immu-
noreactive gold particles in both proliferating and confluent
U-373 cells following HuIFN a-2b treatment was due to
either conformational changes in PKC-a or -13 resulting in
unfolding of the molecule and exposure of more antigenic
sites (the “hinge” region) or to increased synthesis of PKC-a
or -13, Western blots were performed, and the content of
PKC-a and -13after HuIFN ct-2b treatment was compared.
If the changes in PKC-a or -13 immunoreactive gold par-
tides were due to conformational unfolding, then total
(cytosolic, nuclear, and membranous) PKC content as
judged by Western blots would remain the same. Alter-
natively, if the content of PKC-a or -13 increased, Western
blots would depict a change in PKC-a or -13 immunore-
activity. Western blots of PKC-a and -13 in both prolifer-
ating and confluent cells after HuIFN a-2b treatment are
shown in Fig. 1 2. Immunoreactivity to PKC-f3 (Fig. 12, C
and D) is greater than PKC-a (Fig. 1 2, A and B), possibly
due to longer times of chemiluminescence exposure.
Resulting densitometnic scans of PKC-a in proliferating
cells (Fig. 1 2A), confluent cells (Fig. 1 28), and PKC-13 in
confluent cells (Fig. 1 2D) demonstrated decreases in im-
munoreactivity following HuIFN a-2b treatment. Since
similar changes were noted in another experiment and no
increases in PKC-a were observed at 1 mm after HuIFN-
a2b treatment, the differences between immunoblot data
and in situ immunogold labeling data may reflect rapid
turnover and degradation. The content of PKC-j3 immu-
noreactivity in proliferating cells remained constant at 1
mm and decreased by 14% at 2 mm and 31% at 10 mm
of HuIFN a-2b treatment. Again, no increase in PKC-13
immunoreactivity was obtained at 1 mm after HuIFN
a-2b treatment. These results suggest that the increase in
immunogold particles to PKC-13 in proliferating U-373 is
due to unfolding of antigenic sites (hinge region) and
increases in in situ PKC-j3 immunogold labeling, whereas
the decrease seen at 2 and 1 0 mm after HuIFN a-2b
suggests turnover and degradation.
Discussion
Previous efforts to determine the subcellular movement of PKC
following activation have used immunofluorescent (26, 27) or
subcellular fractionation techniques (28). A difficulty in using
light microscopy and either immunofluorescent or immuno-
histochemical techniques for PKC localization after activation
is that the precise subcellular distribution of PKC, i.e., nuclear
or penmnuclear, cytoplasmic or microsomal, microfilamentous
or mitochondrial, is not known (Fig. 48). Alternatively, sub-
cellular fractionation of PKC before and after activation is also
not optimal, since membrane isolation procedure involves
cellular lysis, which may result in release and partial associa-
20
10
0
0 1 2 10
Minutes post HuIFN alpha-2B treatment
Fig. 6. Temporal distribution of cytoplasmic and nuclear immunogold par-
tides (PKC-13) in proliferating nonconfluent and confluent U-373 glioma cells
following HuIFN cs-2b treatment. A, proliferating nonconfluent cells; B,
confluent U-373 cells. Mean immunogold particle density (counts/pm2; bars,
SEM) was quantitated from five cells at three different cytoplasmic and
nuclear locations. All data were obtained by random selection of cell sec-
tions on grids. HuIFN e-2b (500 units/mI). EL cytoplasm; , nucleus. Anti-
body dilutions are as described in “Materials and Methods.”
treatment, PKC-a labeling returned to near control levels in
both the cytoplasm and nucleus. Quantitation of the tem-
poral effects of HuIFN ct-2b on PKC-a immunogold Ia-
beling in confluent cells demonstrated decreased label-
ing in both the cytoplasm and nucleus (Fig. 9B).
Cytoplasmic PKC-a labeling decreased by 59% at 1 mm,
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Fig. 7. Immunogold transmis-
sion electron micrographs of
PKc-g3 labeling in nonconfluent
U-373 cells after HuIFN a-2b
treatment. Cytoplasm (left) and
nucleus (right) of cells treated
with DPBS (control) or HuIFN
a-2b (500 units/mI) for 0 mm (A
and B), 1 mm (Cand 0), 2 mm (E
and F), and 10 mm )G and H).
Note increased gold particle den-
sity in both cytoplasm (C) and nu-
cleus (0) of cells treated with
HuIFN a-2b for 1 mm. x 29,491.
Antibody dilutions are as
described in “Materials and
Methods.”
tion of cytoplasmic PKC isozymes with intracellular organelles
and the plasma membrane. In addition, detergent extraction of
membrane PKCs results in general membrane PKC contami-
nation of the preparation since both plasma membrane PKCs
and membrane-bound organelle PKCs are introduced at
solublization.
The present study has attempted to circumvent the afore-
mentioned predicaments by using immunogold labeling
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Fig. 8. Inimunogold transmis-
sion electron niicrographs of
PKC-/3 labeling in confluent
U-373 cells after HuIFN o-2b
treatment. Cytoplasm (left) and
nucleus (right) of cells treated
with DPBS (control) or HuIFN
a-2b (500 units/mI) for 0 mm (A
and B), 1 mm )Cand 0), 2 mm
(F and F), and 10 mm (G and
H). x 29,491. Antibody dilu-
tions are as described in “Ma-
terials and Methods.”
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and TEM to ultrastructurally define the movement and
location of PKCs after activation. Previous studies have
shown translocation of the glucocorticoid receptor to the
nucleus following steroid binding (24, 25). We used the
dexamethasone-glucocorticoid receptor model to dem-
onstrate that ultrastructural translocation can be docu-
mented using immunogold labeling and TEM. These re-
suits depicted increased immunogold labeling of the
I15.0 -
12.5
;10.0
4)
E
. 7.5
a)
0.
“) 5.0
2.5
0.0
1
A
U)
4)
C)
a
0.
V
0
a,
0
C
E
E
a
0.
a
()
a-
B
I
[LI
I
15.0
12.5
C”
a,
C)
. c10.0
V
 . 7.5
E
Ea
.- 0.
. “0
 2.5
0.0
0 1 2 10
Minutes post HuIFN alpha-2b treatment
Fig. 9. Temporal distribution of cytoplasmic and nuclear immunogold par-
tides (PKC-a) in proliferating and confluent U-373 glioma cells following
HuIFN a-2b treatment. A, proliferating nonconfluent cells; B, confluent cells.
Mean immunogold particle density (counts/pm2; bars, SEM.) was quantitated
from five cells at three different cytoplasmic and nuclear locations. All data
were obtained by random selection of cell sections on grids. HuIFN a-2b
(500 units/mI). El cytoplasm; , nucleus. Antibody dilutions are as described
in “Materials and Methods.”
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glucocorticoid receptor within the nucleolus following
dexamethasone treatment.
The effect of HuIFN a-2b on PKC-a and PKC-13 ultrastruc-
tural localization in U-373 glioma cells was subsequently
evaluated using immunogold labeling and morphometry in
both proliferating and confluent cultures. Previous studies
examining total PKC activity in either proliferating or con-
fluent cells have reported increased total membrane PKC
activity in rapidly growing proliferating cells and increased
cytosolic PKC activity in confluent cells (29, 30). With the
identification of numerous PKC isozymes, this area of re-
search has evolved considerably. We have initially inves-
tigated the subcellular distribution of U-373 PKC-a and -13
and are presently examining different classes and subspe-
cies of PKCs to determine their organelle association and
modulation by HuIFN-a.
The morphometnic data presented herein illustrates that
PKC-a and -13are present in the cytoplasm and nucleus of
both proliferating and confluent cells, but their distribution
is different. There was less total cytoplasmic and nuclear
PKC-a in untreated proliferating U-373 cells than in con-
fluent cells, but the ratio of cytoplasmic to nuclear PKC-a is
similar in both untreated proliferating and confluent U-373
cells. In contrast, both proliferating and confluent cells have
more nuclear PKC-13 compared to cytoplasmic PKC-13. Ex-
posure of proliferating cells to HuIFN a-2b increased im-
munoreactive cytoplasmic and nuclear PKC-13 at 1 mm and
decreased cytoplasmic and nuclear PKC-a at 2 mm. In
confluent cultures, there was no significant change in nu-
clear PKC-j3, whereas cytoplasmic PKC-13 decreased at
2 mm.
Western blots of total PKC-cs in proliferating and conflu-
ent cells and PKC-13 in confluent cells showed results that
may reflect turnover and degradation. Western blots of
PKC-f3 in proliferating cells demonstrated no detectable
change in PKC-f3 immunoreactivity at 1 mm of HuIFN a-2b
treatment and a decline in PKC-13 immunoreactivity at 2 and
10 mm of HuIFN a-2b. These results suggest that the in-
crease in PKC-13 immunogold particles observed in electron
micrographs of proliferating cells following 1 mm of HuIFN
a-2b treatment may be due to conformational unfolding of
PKC-f3 and that the decline in PKC-a and -13at 2 and 1 0 mm
after HuIFN a-2b may be due to proteolytic turnover of
PKC-f3.
The conformational change in PKC-f3 may be due to
exposure of its hinge region. This region is not exposed in
unactivated PKC. Antibodies to PKC-13 were raised to a
peptide corresponding to the hinge or V3 region of PKC.
This region is exposed upon membrane binding of the
enzyme, and its exposure causes PKC to become more
susceptible to proteolysis (31). The enhanced levels of in
situ PKC-j3 immunogold labeling as detected with antibod-
ies directed to the hinge region are consistent with PKC-j3
binding to membranes and its subsequent activation and
turnover by proteolysis.
No translocation of either PKC-a or -13 to specific sub-
cellular organelles was observed in either proliferating or
confluent cells following exposure to HuIFN cs-2b. Unlike
the translocation of PKC isoforms between the cytoplasm,
nucleus, and other membranes, which is found following
activation when conventional membrane separation tech-
niques are used, PKC-a and -13 in U-373 glioma cells ap-
pears to be activated without its actual movement. There-
fore, PKC-a and -13 must be in close proximity to
intracellular membrane structures. The similarities in the
lack of specific PKC-a and -13 organelle translocation fol-
lowing HuIFN a-2b treatment of proliferating and confluent
cells may reflect analogous functions of PKC isozymes
within a family of PKC subspecies. However, we interpret
the differences in nuclear distribution of PKC-a and -13 to
mean that PKC-a and -13 may mediate similar but special-
ized functions within the cell. The differences in expression
mode of PKC-a and -13 following HuIFN a-2b treatment
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may depend on the proliferative state of U-373 glioma cells,
suggesting that activation of PKC isozymes in response to the
antitumor effects of HuIFN a-2b is regulated by the cell cycle.
We are currently characterizing the ultrastructural effects
of HuIFN a-2b on PKC--y and the new and atypical PKCs as
part of an intracellular description of the structural associ-
ations of PKC isozymes.
Materials and Methods
Passage of U-373 Glioma Cells. Glioma U-373 cells were
cultured according to Ponten and Maclntyre (19). Cells
were seeded (1 X 10”) on 75 cm2 flasks containing MEM,
10% FCS, 2 mM L-glutamine, and antibiotics (10 units/mI
penicillin and 10 mg/mi streptomycin).
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Isolation of RNA and RT-PCR. Total cellular RNA was
obtained using a single-step method (23). Generation of
single-stranded cDNA templates for RT-PCR was carried
out on total RNA using SuperScript reverse transcriptase
(Life Technologies, Inc.) according to product instruction
for first-stranded synthesis. Controls for template contami-
nation were as described. The cDNA was divided into two
equal aliquots, and two primer sets were used to amplify
Fig. 1 1. Immunogold transmis-
sion electron micrographs of
PKC-a labeling in confluent
U-373 cells after HuIFN a-2b
treatment. Cytoplasm (left) and
nucleus (right) of cells treated
with HuIFN a-2b (500 units/mI)
for 0 mm (A and B), 1 mm (Cand
D(, 2 mm (Eand F), and 10mm (C
and H). X 29,491 . Antibody dilu-
lions are as described in “Materi-
als and Methods.”
PKC-131 and -1311as described (22): (a) sense primer corre-
sponding to the V3 region of PKC-f3 (ATGAAACTGAC-
CGATTTTAACTTCCTG) and antisense primer correspond-
ing to the VS region of PKC-f3I (AAGAGTTTGT-
CAGTGGGAGTCAGTTCC); or (b) sense primer corre-
sponding to the V3 region of PKC-13 and antisense primer
corresponding to the VS region of PKC-j3I1 (CGGAGGTC-
TACAGATCTACTTAGCTCT). For all primer pairs, the cy-
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4 R. Gopalakrishna, personal communication.
Fig. 12. Western blot analysis ot
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PKC-j3.
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Treatment
cling conditions were an initial 96#{176}Cmelt for 5 mm, fol-
owed by 58#{176}Cfor 1 mm, followed by 72#{176}Cfor 3 mm.
Following 95#{176}Cfor 1 mm, this cyclewas repeated 34 times,
ending with 95#{176}C,1 mm; 58#{176}C,1 mm; and 72#{176}C,10 mm.
Specificity of the primers was verified with cDNA for
PKC-131 and -1311 (from Dr. John Knopf, Genetics Institute,
Inc., Cambridge, MA). The RT-PCR data demonstrate that
PKC-f31 and -1311 are present in U-373 human glioma cells.
The assays are not quantitative.
Total Extraction of U-373 Glioma PKC. For extraction of
total U-373 glioma PKC, cells were washed with DPBS, and
flasks were placed on ice. Monolayers were scraped at 4#{176}C
and sonicated in homogenization buffer 110 m Tris/HCI
(pH 7.5), 10 mM EGIA, 25 mtvt MgCl2, 2 msi DTT, 0.25 M
sucrose, 2 mts phenylmethylsulfonyl fluoride, 0.4 mi leu-
peptin, and 0.15 unit/mI aprotinini containing 1% Triton-
x-1 00. Cell homogenates were centrifuged at 1 00,000 X g
for 30 mm to obtain total extractable PKC.
Procedure for Immunoblotting. Total U-373 extractable
PKC (50-200 pg of protein) was subjected to SDS-PAGE
(9% gel) according to the method of Laemmli (32). Proteins
were electrophoretically transferred to nitrocellulose ac-
cording to Towbin et a!. (33). Equipment, reagents, and
procedures were from Bio-Rad (Melville, NY). immunore-
active bands were visualized with chemiluminesence (Am-
ersham, Arlington Heights, IL).
Antibodies and Specificity of Antipeptide Antisera to
PKC-a and -3. Peptides and antibodies to PKC-ct, PKC-f3
(131+1311), -j31, and -1311 were produced, characterized, and
kindly provided to us by Dr. Rayudu Gopalakrishna (Uni-
versity of Southern California, Los Angeles, CA). They were
raised to peptides synthesized from oligopeptide sequences
unique to PKC-a, -13, -131, and -1311 using previously pub-
lished sequences reported to have good antigenicity (34,
35) at the USC Norris Comprehensive Cancer Center. An-
tibodies were raised to protein conjugated peptides in New
Zealand White rabbits.
The PKC-a antibody was raised to amino acid residues
31 3-326 I(C)AGNKVISPSEDRRQI that correspond to the
hinge region of PKC-a. The PKC-a oligopeptide sequence
was coupled to hemocyanin using m-maleimido-benzoyl
N-hydroxysuccinimide (34). Antibodies to PKC-j3 were
raised to amino acid residues C13-C39 (GPKTPEEKTAN-
TISKFD), which corresponds to the hinge or V3 region of
PKC-f3 (35). This antibody does not distinguish between
PKC-pl or -1311.Antibodies to PKC-13l and -1311were raised to
the COOH-terminal peptide sequences of PKC-f31 (SYT-
NPEFVINV) and 1311 (SFVNSEFLKPEVKS), which couple to
thyroglobuin using glutaradehyde (35). The last 50 amino
acids of PKC-13l are different from -1311 due to alternative
splicing of a common primary transcript.
Western blots to characterize the antipeptide antisera
used alkaline phosphatase-conjugated anti-rabbit goat an-
tibodies as the second antibody and gave positive staining
at 1 :1000 dilution compared to preimmune serum.4 Coin-
cubation of antibodies with peptides to PKC-a and -13 and
not with unrelated peptides blocked positive staining.4
Blocking experiments using Western blots were per-
formed in the present study to demonstrate that antipeptide
antisera were mono-specific for PKC-a and -13 and that cross
reactions with other U-373 glioma cellular proteins could
be eliminated from consideration. Confluent U-373 glioma
cells were treated with HuIFN a-2b (500 units/mI) for 0, 1,
2, or 1 0 mm as stated below. Total cell homogenates con-
taming either 1 00 pg of protein for assaying PKC-a or 200
pg of protein for probing PKC-13 were loaded/lane on SDS-
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PAGE for Western blots. Peptides to PKC-a and -13 (300 il
containing 300 pg) were incubated overnight with 1 ml of
milk and 50 p1 of antibody. The antibody-peptide mixture
was diluted with milk at 7:1 000 and used for Western blots
and enhanced chemiluminescence (Amersham Corp.).
in Vitro Treatment of U-373 Glioma Cells with HuIFN
a-2b. In vitro studies were performed according to Ace-
vedo-Duncan eta!. (36). Subconfluent (75%) and confluent
cells were washed three times with DPBS, 2 h prior to
treatments with either DPBS (control) or HuIFN a-2b (500
units/mI) for 0, 1 , 2, or 1 0 mm. Treatments were terminated
by fixing cells in 0.5 glutaraldehyde/2% paraformaldehyde.
Indired Immunofluorescence Microscopy. Indi rect im-
munofluorescence microscopy was performed by modifi-
cation of the procedure of Chida et a!. (1 3). Glioma U-373
were grown on Lab-Tek chamber slides (Nunc Inc., Naper-
ville, IL). When the desired cell density was reached, cells
were washed twice with 2 ml of PBS and treated for differ-
ent time periods with HuIFN a-2b (in 2 ml of PBS) as
described above. Treatment with HuIFN a-2b was termi-
nated by fixation of cells in 3.7% formaldehyde for 1 5 mm.
After washing cells twice with PBS, slide were blotted and
permeablized with cold (-4#{176}C)100% ethanol for 10 mm at
-4#{176}C.ells were then air dried, and nonspecific sites were
blocked with heat-inactivated 3% goat serum for 30 mm.
Cells were subsequently washed twice with PBS and incu-
bated with either nonimmune serum, antipeptide PKC-a, or
antipeptide PKC-f3 at a 1 :20 dilution for 1 h. Cells were
washed three times with PBS and incubated in the dark with
fluorescein-conjugated goat anti-rabbit lgG (Hyclone, Lo-
gan, UT) for 1 h at a 1 :50 dilution. Cells were washed three
times with PBS and twice with water to remove salts. Slides
were mounted with Fluromount (Fisher, Pittsburgh, PA),
and immunofluorescence was observed using a Lietz Labor
Lux microscope with an incident fluorescence attachment
(LEP, Inc.) and a filter cube appropriate for fluorescein.
Kodak Tri-X Pan 400 film was used to photograph the
fluorescence.
Procedure for Immunogold Labeling and TEM. Fol-
lowing specific treatments, cells were fixed in 0.5% glutar-
aldehyde/2% paraformaldehyde in DPBS for 10 mm. Cells
were washed three times in DPBS by centrifugation and
fixed overnight in 2% paraformaldehyde in DPBS at 4#{176}C.
The next day, dehydration was accomplished by 5-mm
stepwise gradients up to 80% ethanol. Cells were infiltrated
with a 2:1 mixture of LR white (Electron Microscopy Sci-
ences, Fort Washington, PA) to 80% ethanol for 1 h at room
temperature (37). Two 1-h infiltrations in 1 00% LR white
followed, and a third infiltration in 1 00% LR white was left
overnight at 4#{176}C.The next day, cells were infiltrated in
1 00% LR white at room temperature and transferred to
BEEM capsules for polymerization for 48 h in a light tight
UV box at room temperature.
Sectioning. Blocks were sectioned on a Jung Reichert
Ultracut E ultramicrotome using a Diatome diamond knife.
Approximately 80-nm (pale-gold) thin sections were col-
lected in distilled water and transferred to nickle formvar-
coated grids using a wire loop. After drying, the sections
were labeled by immunogold technique described below.
lmmunogold Technique. Sections were incubated (at
room temperature) by floating them face down on droplets
of solutions on parafilm affixed to the bench top. The pro-
cedure of Hailer et a!. (38) was used. Sections were pre-
treated with Tris-buffered saline (TBS) with 5% FCS for 20
mm and washed with TBS-AGT [TBS containing 0.1 % BSA,
0.2% coldwater fish gelatin (Sigma Chemical Company, St.
Louis, MO) and 0.05% Tween 20] for 1 0 s each. Primary
antibody (rabbit anti-PKC-a and -13) at 1 :20 dilution in
TBS-AGT was applied for 2 h and washed five times with
TBS-AGT for 5 mm each. Nonimmune rabbit serum at a
1 :20 dilution was used as the control for the primary anti-
body. The second antibody (goat anti-rabbit lgG conjugated
to 10-nm gold particles; Amersham) was at a 1 :50 dilution
and was incubated for 1 h in the dark. Sections were
washed three times with TBS-AGT for 5 mm each and then
washed for 5 mm in TBS, followed by distilled water, and
allowed to dry on filter paper. Counterstaining was per-
formed with saturated uranyl acetate for 1 mm and with 1
M lead citrate for 30 s to enhance the contrast of cellular
ultrastructure. Controls were run concurrently using rabbit
preimmune serum to test for antibody specificity. Sections
were examined on a Phillips CM-i 0 electron microscope at
60KV to minimize resin instability. Micrographs were taken
on Kodak electron microscope film (Estar thick base) and
developed with Kodak D-19 developer. Prints were on Ko-
dabrome RC paper developed with an Ektamatic processor.
Morphometry. The morphogenetic effects of HuIFN
a-2b on PKC-a and -13 intracellular localization was as-
sessed on serial sections cut from one block for each of the
different time treatments. Two separate experiments were
performed, and two separate sets of immunogold-labeled
grids were photographed for analysis. Five cells from each
set were photographed at X2i ,000, and micrographs were
printed at X35,700. The number of immunogold particles
present in three different cytoplasmic locations and three
different nuclear locations/cell were quantified from micro-
graphs of five different cells for each treatment. Particle
densities were expressed as mean gold particles/micrometer
square. Statistical determination ofgold particle density was
by Student’s t test using Minitab software (Minitab, Inc.,
State College, PA).
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